$-0.01
(Market cap
$970 Mln
Revenue (TTM)
$205 Mln
P/E Ratio
--
P/B Ratio
4.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-9.1
-
Debt to Equity
0.5
-
Book Value
$--
-
EPS
$-0.1
-
Face value
--
-
Shares outstanding
642,473,409
10 Years Aggregate
CFO
$-575.30 Mln
EBITDA
$-710.51 Mln
Net Profit
$-705.37 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Geron (GERN)
| 12.1 | 14.7 | 18.4 | 5.7 | -15.2 | 0.4 | -5.8 |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Geron (GERN)
| -62.7 | 67.1 | -12.8 | 98.4 | -23.3 | 16.9 | 36.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Geron (GERN)
|
1.5 | 970.1 | 204.6 | -69.9 | -20.8 | -31.4 | -- | 4.5 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 260.3 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 71.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 363.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Geron (GERN)
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to... intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California. Read more
-
Chairman of the Board, President & CEO
Dr. John A. Scarlett M.D.
-
Chairman of the Board, President & CEO
Dr. John A. Scarlett M.D.
-
Headquarters
Foster City, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Geron (GERN)
What is the current share price of Geron Corporation (GERN) Today?
The share price of Geron Corporation (GERN) is $1.48 (NASDAQ) as of 01-Sep-2026 16:00 EDT. Geron Corporation (GERN) has given a return of -15.23% in the last 3 years.
What is the current PB & PE ratio of Geron Corporation (GERN)?
Since, TTM earnings of Geron Corporation (GERN) is negative, P/E ratio is not available.
The P/B ratio of Geron Corporation (GERN) is 4.50 times as on 28-Aug-2026, a 13 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-10.27 |
3.90 |
2024 |
-13.10 |
8.16 |
2023 |
-6.82 |
5.06 |
2022 |
-6.96 |
12.35 |
2021 |
-3.48 |
3.19 |
What is the 52 Week High and Low of Geron Corporation (GERN)?
The 52-week high and low of Geron Corporation (GERN) are Rs 2.01 and Rs 1.04 as of 02-Sep-2026.
What is the market cap of Geron Corporation (GERN)?
Geron Corporation (GERN) has a market capitalisation of $ 970 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Geron Corporation (GERN)?
Before investing in Geron Corporation (GERN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.